Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05454410CT.gov Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) | — | Completed | — | — | — |
NCT03756129CT.gov Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Onfasprodil (this asset) | Novartis Pharmaceuticals | P2 | B · 62 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Saredutant | Sanofi | P3 | BBB |
| VENLOR | Janssen Research & Development, LLC | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | VA Office of Research and Development | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
| Citalopram | Western University, Canada | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for Onfasprodil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Major Depressive Disorder | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Onfasprodil in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/onfasprodil-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →